Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group

References

• Kish SG, Weaver A, Jacobs, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819–1824
   PubMed Web of Science ®Google Scholar
• Rowland KM, Taylor SG, Spiers AS, DeConti RC, O'Donnell MR, Showel J, et al. Cisplatin and 5-fluorouracil infusion chemotherapy in advanced recurrent cancer of the head and neck. An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 1986; 70: 461–464
   PubMedGoogle Scholar
• Creagan ET, Ingle JN, Shutt AJ, O'Fallon JR, et al. A phase II study of cis-diamminedichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasm. Head Neck Surg 1984; 6: 1020–1023
   PubMedGoogle Scholar
• Dasmahaparta KS, Citrin P, Hill GJ, Yee R, Mohit-Tabatabai MA, Rush BF, Jr, et al. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous cell cancer of the head and neck. J Clin Oncol 1985; 3: 1486–1489
   PubMedGoogle Scholar
• Amrein PC, Weitzam SA. Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985; 3: 1632–1639
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase II randomized study compariting cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257–263
   PubMed Web of Science ®Google Scholar
• Forastiere A, Metch B, Schuller D, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245–1251
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristin (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521–526
   PubMed Web of Science ®Google Scholar
• Merlano M, Tatarek R, Grimaldi A, Margarino G, Rossa R. Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: An effective outpatient schedule. Cancer Treat Rep 1985; 69: 961–964
   PubMedGoogle Scholar
• Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327: 1115–1121
   PubMed Web of Science ®Google Scholar
• Forastiere A, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82: 2270–2274
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19: 1088–95
   PubMed Web of Science ®Google Scholar
• Murphy B, Li Y, Cella D, Karnad M, Hussain A, Forestiere A, et al. Phase III Study Comparing Cisplatin (C) & 5-Fluorouracil (F) Versus Cisplatin & Paclitaxel (T) in Metastatic/Recurrent Head & Neck Cancer (MHNC). Proc ASCO 2001; 20: 224 (abstr 894)
   Google Scholar
• Benasso M, Numico G, Rosso R, Merlano M, Ricci I, Gentile A. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study. Semin Oncol 1997; 24(6 Suppl 19): S19-46–S19-50
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–210
   PubMed Web of Science ®Google Scholar
• Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45: 537–547
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meyer P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457–474
   Google Scholar
• Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999; 86: 2364–2369
   PubMed Web of Science ®Google Scholar
• Worden FP, Moon J, Samlowski W, Clark J, Dakhil SR, Taylor SA, et al. A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study. Proc ASCO 2004; 22: 491 (abstr 5512)
   Google Scholar
• Hitt R, Jimeno A, Millan JM, Castellano D, Cortes-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer 2004; 101: 768–775
   PubMed Web of Science ®Google Scholar
• Hitt R, Paz-Ares L, Brandáriz A, Castellano D, Pena C, Millan JM, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Onc 2002; 13: 1665–1673
   PubMedGoogle Scholar
• Hitt R, Lopez-Pousa A, Rodriguez M, Martinez-Trufero J, Cervantes A, Carles J, et al. Phase III study comparing cisplatin (P) & 5-fluorouracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC). Proc ASCO 2003; 22: 496 (abstr 1997)
   Google Scholar
• Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11: 845–849
   PubMed Web of Science ®Google Scholar
• Gedlicka C, Formanek M, Selzer E, Burian M, Kornfehl J, Fiebiger W, et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 2002; 63: 145–150
   PubMed Web of Science ®Google Scholar
• Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicentre phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamuos cell cancer of head and neck. J Clin Oncol 2001; 19: 1096–1104
   PubMed Web of Science ®Google Scholar
• Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma oof the head and neck (SCCHN). Am J Clin Oncol 2002; 25: 153–159
   PubMed Web of Science ®Google Scholar
• Schijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Ann Oncol 2004; 15: 638–645
   PubMedGoogle Scholar
• Vermorken JB, Remenar E, Van Herpen C, Germa Lluch J, Stewart S, Gorlia T, et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectablelocally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group. Proc ASCO 2004; 22: 490 (abstr 5508)
   Google Scholar